Chikungunya Global Market Report 2025

The chikungunya market size has grown strongly in recent years. It will grow from $0.59 billion in 2024 to $0.65 billion in 2025 at a compound annual growth rate (CAGR) of 9.8%. The growth during the historic period can be attributed to factors such as rising per capita healthcare expenditures, the growing prevalence of emerging and re-emerging infectious diseases, increased personal disposable income, climate change, and heightened awareness of mosquito-borne diseases.

The chikungunya market size is expected to see strong growth in the next few years. It will grow to $0.93 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. The growth during the forecast period can be attributed to factors such as a global increase in clinical trials, a growing geriatric population, a rising demand for immunization, expanding government and non-government initiatives, increased government investments, and favorable policies. Key trends during this period include advancements in biotechnology for vaccine development, new opportunities in vaccine research, the use of CRISPR and AI for innovative solutions, strategic collaborations among pharmaceutical companies, and the integration of telemedicine services.

The increasing prevalence of mosquito-borne diseases is expected to drive the growth of the chikungunya market in the coming years. Mosquito-borne diseases, including chikungunya, dengue, and the Zika virus, are transmitted to humans through infected Aedes mosquitoes and present significant global public health challenges. The rising incidence of these diseases is influenced by factors such as climate change, urbanization, deforestation, stagnant water accumulation, insufficient vector control measures, increased global travel, and insecticide resistance. Chikungunya treatment helps patients by alleviating symptoms such as fever, joint pain, and inflammation, improving overall comfort and mobility, reducing complications, and promoting recovery through hydration, pain management, and supportive care. For instance, in December 2024, the UK Health Security Agency reported that between January and June 2024, the number of dengue cases among returning travelers in England, Wales, and Northern Ireland surged to 473, a 201% increase compared to the 157 cases reported during the same period in 2023. This growing global incidence of mosquito-borne diseases is fueling the growth of the chikungunya market.

Leading companies in the chikungunya market are focusing on the development of innovative vaccines to enhance immunity, prevent disease outbreaks, and address the rising global health burden of chikungunya virus infections. One such innovation is the live attenuated chikungunya vaccine, which uses a weakened form of the virus to stimulate an immune response without causing the disease, providing long-term protection. For example, in November 2023, Valneva SE, a France-based biotechnology company, announced the approval of IXCHIQ, a live attenuated chikungunya vaccine, by the U.S. Food and Drug Administration (FDA). This approval was granted under accelerated approval based on anti-CHIKV neutralizing antibody titers, with continued approval contingent on confirming clinical benefits in further studies. Valneva also received a Priority Review Voucher (PRV) from the FDA, which it plans to monetize to support its research and development efforts. IXCHIQ is administered as a single-dose injection and contains a live, weakened form of the chikungunya virus, which may cause mild symptoms similar to the disease.

In February 2023, Bavarian Nordic A/S, a Denmark-based biotechnology company, acquired the travel vaccine portfolio from Emergent BioSolutions Inc. for USD 380 million. This acquisition aims to strengthen Bavarian Nordic's position in the travel vaccine market by adding marketed vaccines such as Vivotif for typhoid fever prevention, Vaxchora for cholera prevention, and a phase 3 vaccine candidate for chikungunya virus prevention. Emergent BioSolutions Inc., a US-based life sciences company, also offers chikungunya vaccines.

Major players in the chikungunya market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Quest Diagnostics Incorporated, Eurofins Scientific SE, Grifols Diagnostic Solutions Inc., bioMérieux SA, Bio-Rad Laboratories Inc., DiaSorin S.p.A., Euroimmun AG, Evotec SE, Valneva SE, ELITechGroup S.A.S., Vaxart Inc., BioPerfectus Biotechnology Co. Ltd., CTK Biotech Inc., Creative Diagnostics Inc., Inovio Pharmaceuticals Inc., Biotrol Laboratories Pvt. Ltd.

North America was the largest region in the chikungunya market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in chikungunya report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chikungunya market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Chikungunya (CHIKV) is a viral infection caused by the chikungunya virus, primarily transmitted to humans through the bites of infected Aedes aegypti and Aedes albopictus mosquitoes. The infection causes symptoms such as fever, joint pain, headache, rash, and muscle pain, which significantly affect the quality of life of those who are infected.

The main product types for chikungunya include antiviral drugs, herbal and complementary treatments, supportive care, and vaccines. Antiviral drugs are designed to prevent or treat viral infections by inhibiting the replication of viruses in the body. These medications come in various forms, such as liquids, powders, and solids, and are used at different stages of the disease, including acute, chronic, and post-infection stages. These products are distributed through a variety of sales channels, including hospital pharmacies, online pharmacies, retail pharmacies, and supermarkets, and are used by various end users such as caregivers, healthcare professionals, and patients.

The chikungunya market research report is one of a series of new reports that provides chikungunya market statistics, including the chikungunya industry global market size, regional shares, competitors with the chikungunya market share, detailed chikungunya market segments, market trends, and opportunities, and any further data you may need to thrive in the chikungunya industry. This chikungunya market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chikungunya market consists of revenues earned by entities by providing services such as vaccination services, diagnostic testing services, and consultation and medical care. The market value includes the value of related goods sold by the service provider or included within the service offering. The chikungunya market also includes sales of vaccines, diagnostic kits, supportive therapies, and diagnostic equipment. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.